RxDoctor Payments Data

Callie Rothwell, APRN

Family · Metairie, LANPI 1629441282

Payments from drug & device makers

$4,864in general payments, 2019–2025

Across 216 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • AstraZeneca$884
  • Sanofi$410
  • GSK$375
  • Takeda Pharmaceuticals U.S.A., Inc.$304
  • AbbVie$291
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,864 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$38,348
Medicare patients
121
Services billed
1,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,876
Spiriva RespimatTiotropium Bromide12$6,344
Breo ElliptaFluticasone/Vilanterol11$5,160
SymbicortBudesonide/Formoterol Fumarate21$4,784
Ipratropium Bromide45$1,632
Fluticasone Propionate93$1,575
Azelastine Hcl38$1,007
Ofloxacin36$740
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav41$546
Doxycycline Hyclate37$453
Omeprazole30$435
Albuterol Sulfate HfaAlbuterol Sulfate24$430
Famotidine19$208
Pantoprazole Sodium20$193
Methylprednisolone26$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$375$24,03740 claims
AstraZenecaSymbicort$884$4,78421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.

Other family in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →